ClinicalTrials.gg
Status unknownNCT05803538Updated Apr 7, 2023

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

An interventional study of SMS, telephone interview or diary card in Measles, sponsored by Dilla University. Status unknown at 1 site in Ethiopia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Dilla University · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
391
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction Participant centered active adverse event following immunization (AEFI) surveillance can offer real time vaccine safety data and help in signal detection. Evidence showed that it is still difficult to get AEFI from passive reporting in Ethiopia. Vast novel method of enhanced AEFI surveillance has been practiced globally. However, those methods had serious limitations including the requirement of high resource and expertise. Hence, there is a need to find the most flexible low cost and integrated AEFI surveillance system. To the best of our knowledge, there has no published research in Ethiopia which compare Participant diary, SMS, and telephone interview for the purpose of active AEFI surveillance.

Objective: To assess participant centered active adverse event surveillance following measles immunization at Gedeo Zone health facilities, Ethiopia.

Method: An open randomized trial will be employed from October 1, 2022- December 1, 2023, at Gedio Zone health facilities. All parents, care givers/guardians whose child receive vaccine during the study period in the study site will be included in the study. A total of 391participants will be randomized to SMS, telephone interview or diary card group using random number generator on Excel. Every participant will be contacted on day seven to request them whether they experience any AEFI. Differences in proportions will compared using chi-square tests. A 0.05 level of significance will be used for all analyses. Independent sample t-tests will be used to compare the mean time (in days) required to collect complete AEFI data by SMS, telephone interview and diary card. Multinominal logistic regression analyses will be used assess the factors associated with effective use of tailored SMS, telephone interview and diary card for the AEFI active surveillance. To further investigate the association between the vaccine and the adverse events and factors associated with vaccine binary and multi variable logistic regression will be used.

02

Conditions studied

  • Measles

Browse trials for

Keywords

  • Participant Centered Active Surveillance
  • Adverse Event
  • Measles Immunization
03

In context

Measles

134 studies on the registry are indexed under Measles; 17 are open to participants now.

This study's planned enrollment of 391 is below the median of 852 across 105 interventional studies indexed under Measles.

Browse Measles studies →

Lead sponsor

Dilla University is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents, care givers/guardians, whose child receive vaccine.
  • ≥18 years of age.
  • Willing to adhere to study procedures, which will include a randomization.
  • Willing to participate

Exclusion criteria

Exclusion Criteria:

  • Unable to give because of cognitive impairment.
  • Those who are both illiterate and don't have mobile phone.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
391 participants (estimated)

Study arms

  • Experimental
    SMS

    Device: SMS, telephone interview or diary card

  • Experimental
    Telephone interview

    Device: SMS, telephone interview or diary card

  • Experimental
    Diary card

    Device: SMS, telephone interview or diary card

  • Active comparator
    Usual Care

    Device: SMS, telephone interview or diary card

Interventions

  • DeviceSMS, telephone interview or diary card

    SMS, telephone interview or diary card

06

What researchers measure

Primary outcomes

  1. Response rate

    To compare response rate of tailored SMS, telephone interview and diary card for the AEFI active surveillance

    Time frame: 7 days

Secondary outcomes

  1. AEFI's reported from each group and feasibility of participant centered AEFI active surveillance

    Time frame: 7days

07

Study locations

1 site
  • Dilla University
    Hawassa, Snnpr 419, Ethiopia
    • Dawit G Assefa, MSc · Contactdawitgetachewa@gmail.com · +251912820413
    • · Contactdawitgetachewa@gmail.com
    • Dawit G Assefa, MSc · Principal investigator
    • Tizalegn Tesefaye, MSc · Sub investigator
    • Andualem Meberatu, MSc · Sub investigator
    • Etaferaw Bekele, MSc · Sub investigator
    • Genet Geberemickeal, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2023; primary completion for Dec 2023, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 7, 2023
StartEst.
May 15, 2023
Primary completionEst.
Dec 20, 2023
CompletionEst.
Jan 30, 2024
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05803538
Lead sponsor
Dilla University
Responsible party
Dawit Getachew Getachew (Mr., Dilla University) — Principal investigator
First posted
Apr 7, 2023
Start date
May 15, 2023 (estimated)
Primary completion
Dec 20, 2023 (estimated)
Completion
Jan 30, 2024 (estimated)
Last update
Apr 7, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion